Patents by Inventor Erik Hogbom

Erik Hogbom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Eosinophil Cationic Proteins used in the Treatement of Asthematic and Allergic Disorders
    Publication number: 20060183114
    Abstract: The present invention relates to novel eosinophil cationic proteins characterised by the presence of a single nucleotide polymorphism. The presence of such polymorphism has been correlated to an advantageous phenotype being a reduced disposition to allergic and asthmatic disorders.
    Type: Application
    Filed: May 8, 2001
    Publication date: August 17, 2006
    Inventors: Erik Hogbom, Jonas Bystrom, Ulla-Britt Jonsson, Per Venge
  • Compound for treatment of allergy and asthma
    Patent number: 6986889
    Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-Fc?RI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: January 17, 2006
    Assignee: Pharmacia Diagnostics AB
    Inventors: Sylvia Laffer, Erik Högbom, Kenneth H. Roux, Jonas Adriansson, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Hans Grönlund, Rudolf Valenta
  • Novel compound for treatment of allergy and asthma
    Publication number: 20030035796
    Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma.
    Type: Application
    Filed: March 28, 2002
    Publication date: February 20, 2003
    Applicant: Pharmacia Deagnostics AB
    Inventors: Sylvia Laffer, Erik Hogbom, Kenneth H. Roux, Jonas Adriansson, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Hans Gronlund, Rudolf Valenta
  • Compound for treatment of allergy and asthma
    Patent number: RE42324
    Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-Fc?RI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: May 3, 2011
    Assignee: Phadia AB
    Inventors: Sylvia Laffer, Erik Hogbom, Kenneth H. Roux, Jonas Adriansson, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Hans Grönlund, Rudolf Valenta